KPJ Healthcare Leads ASEAN in Healthcare Brand Strength, Ranks Second in Brand Value

Valuation rises 45% to USD305 million as Group advances 49 places in Brand Finance ASEAN 500 2026

KUALA LUMPUR, Malaysia, Nov. 10, 2026 /PRNewswire/ -- KPJ Healthcare Berhad ("KPJ Healthcare" or "the Group"), Malaysia's first private academic health system, has emerged as ASEAN's strongest healthcare facilities brand in the Brand Finance ASEAN 500 2026 report, with a Brand Strength Index score of 86.8 out of 100.

The Group also secured second place among ASEAN's most valuable healthcare facilities brands, with its brand value rising 45% to USD305 million from USD211 million in 2025. This follows a 71% increase in 2025, extending the Group's growth in brand value for a second consecutive year.

Across all industries, KPJ Healthcare advanced 49 places in the overall ASEAN 500 ranking, from 231^st in 2025 to 182^nd in 2026, placing it among the region's 200 most valuable brands.

Prof. Dato' Dr Hanafiah Harunarashid, Officer-in-Charge of KPJ Healthcare Berhad, said the achievement holds particular significance for a Malaysian healthcare institution with an established presence in the region.

He further commented, "To lead ASEAN in healthcare brand strength is a distinction we are proud of, particularly for a Malaysian healthcare institution that has served generations of patients. It is also a responsibility. The confidence placed in KPJ Healthcare must be matched by the standards of care we deliver and the capabilities we continue to develop. Our priority is to advance specialist care, develop healthcare professionals and translate research and innovation into better patient outcomes. Through KPJ Health System, we are building on these strengths to fulfil our purpose of Care for Life."

KPJ Health System ("KPJHS") connects the Group's hospitals with KPJ Healthcare University and its research capabilities through three core pillars of Practice, Education and Research & Innovation. This enables the Group to develop its own healthcare professionals, advance specialist expertise and pursue research informed by the needs of clinical practice.

That depth of expertise is evident in KPJ's recent clinical achievements. Damansara Specialist Hospital 2 set a Southeast Asian record with 35 robotic-assisted minimally invasive cardiac surgeries in 90 days. It was also the first hospital in Southeast Asia to introduce Supine High-Intensity Focused Ultrasound ("HIFU") for non-invasive fibroid treatment, while KPJ Selangor Specialist Hospital performed the Asia-Pacific region's first HOBBIT minimally invasive cement-screw surgery.

KPJ is extending its specialist capabilities through Centres of Excellence ("CoEs") in Heart & Lung, Neuroscience & Stroke and Orthopaedics & Rheumatology. With a target of 15 CoEs by 2030, the programme aims to deepen specialist expertise, improve coordination of complex care and raise clinical standards across the Group.

KPJ continues to develop its specialist and academic capabilities through strategic relationships with leading medical institutions. Its longstanding relationship with Mayo Clinic includes specialist advisory support for the CoEs and Mayo Clinic Care Network membership at selected KPJ hospitals. KPJ's work with Singapore Health Services ("SingHealth") covers clinical research, education, medical simulation, digital health and artificial intelligence, while its partnership with the Royal College of Surgeons of England, through KPJ Healthcare University, supports surgical education, professional training and research.

KPJ plans to launch its Future Health Institute in 2027 to advance the practical application of research and digital health in clinical care. The Institute will evaluate new approaches to treatment and healthcare delivery for potential adoption across the Group's hospital network.

KPJ has also received recognition for its healthcare services, corporate performance and sustainability initiatives. Earlier this year, eleven KPJ hospitals were included in Newsweek's World's Best Hospitals 2026, while the Group received Hospital Group of the Year (Malaysia) and ESG Program of the Year (Malaysia) at the Healthcare Asia Awards 2026.

The Group secured Euromoney's Malaysia – Best Cash Management Deal Award 2026 and two distinctions at the CorporateTreasurer Awards 2026 for excellence in cash management and sustainability across Southeast Asia. KPJ earned three awards at The Edge Billion Ringgit Club 2026 for its financial performance and a Silver Award at the Asia ESG Positive Impact Awards 2026 for its community healthcare initiatives.

KPJ's health tourism performance also contributes to its presence in the regional healthcare market. Revenue from this segment rose 21% year-on-year in the first half of 2026.

The Brand Finance results mark another significant achievement for KPJ Healthcare as it continues to develop its position among ASEAN's leading healthcare brands. With its academic health system, specialist capabilities and regional patient reach, the Group enters its next phase with a stronger platform for long-term growth.

For more information on KPJ Healthcare, visit https://www.kpjhealth.com.my.

About KPJ Healthcare Berhad
KPJ Healthcare operates 29 hospitals across Malaysia and four Ambulatory Care Centres, serving 3.3 million patients annually with 1,491 medical consultants. Nineteen hospitals are accredited by MSQH and four by JCI. As Malaysia's first private healthcare provider to establish an Academic Health System, KPJHS integrates practice, education and research & innovation to drive clinical excellence and patient experience. Beyond hospitals, KPJ Healthcare operates Klinik Waqaf An-Nur (KWAN) clinics, dialysis centres and mobile clinics nationwide, and offers more than 40 academic programmes at KPJ Healthcare University (KPJU). KPJ Healthcare has been a constituent of the Bursa Malaysia FTSE4Good Index since 2016.

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

KPJ Healthcare Leads ASEAN in Healthcare Brand Strength, Ranks Second in Brand Value

MILAN, MUNICH and SHANGHAI, Nov. 10, 2026 /PRNewswire/ -- On November 3, 2026 EICMA (International Motorcycle and Accessories Exhibition), one of the most influential annual events in the global two-wheel industry, officially opened in Milan, Italy. neueHCT showcased its HCT Orbis Advanced Rider Assistance System, presenting the latest innovations by a Chinese intelligent driving company in the field of intelligent two-wheel mobility to global audiences.

neueHCT specializes in providing comprehensive ADAS and intelligent driving solutions for global OEMs, covering fields such as passenger vehicles, two-wheeled mobility, and L4 autonomous logistics vehicles. Through technical and functional demonstrations, neueHCT showcased HCT Orbis's strengths in ACC, environmental perception, risk warning, and active safety, attracting numerous two-wheeler OEMs, media representatives, industry experts, and visitors.

On the opening day, Stone Li, CEO of neueHCT, gave an exclusive interview at the booth to HD Motori, a renowned Italian technology and automotive media outlet. He shared in-depth insights into HCT Orbis's technical advantages, local adaptation, and global trends in intelligent two-wheel mobility. "When you ride a bike, you are exposed and far more vulnerable than a driver inside a vehicle," said Stone Li. "That is why the technology we develop is aimed at preventing the kinds of traffic accidents that cause the greatest harm to these road users."

To date, neueHCT has served more than 16 OEM customers worldwide including Chery, Volkswagen and Dongfeng Nissan, and won projects covering over 70 vehicle models, with overseas programs accounting for more than 50% of the total. The company has accumulated millions of kilometers of global real-road and over 10 billion kilometers of simulation testing worldwide.

Europe is a key market for global two-wheel industry and riding culture, and a strategically important region in neueHCT's global strategy. neueHCT's passenger vehicles have completed validation in multiple European cities, including Memmingen, Munich, Frankfurt, and Paris, and the experience can support the development and localization of its two-wheeler solutions. The company is also engaged with European two-wheeler OEMs, and its products meet the requirements of E-NCAP and EU GSR II regulations and certifications. Moreover, neueHCT has already established an R&D center in Germany to support product deployment in global markets.

Looking ahead, neueHCT will continue to deepen collaboration with European and global OEMs and industry partners, efficiently delivering intelligent riding assistance solutions that comply with regional regulatory standards, and driving two-wheel mobility toward a safer and smarter future.

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

neueHCT showcases HCT Orbis at EICMA, Bringing Intelligent Driving Technology to Global Two-Wheel Mobility